Axonics' implantable rechargeable sacral neuromodulation device is now FDA-approved for the treatment of fecal incontinence, overactive bladder, and urinary retention. Medtronic is suing Axonics for alleged patent infringement, but the company does not appear to be intimidated.
The rumor mill was lit with a recent Bloomberg report of a potential $8 billion Thermo Fisher-Qiagen deal. Qiagen acknowledged that it has received several "indications of interest" but the company stopped short of revealing the potential buyers.
Hologic dropped $1.65 billion on Cynosure two years ago, but the company has struggled with the business since the beginning and is now throwing in the towel. Cynosure will be acquired by an affiliate of investment funds managed by Clayton, Dubilier & Rice for $205 million.